Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy

AIDS

Volumn 17, Issue 5, 2003, Pages 765-768

  De Gaetano Donati, Katleen ^a   Rabagliati, Ricardo ^a,b   Tumbarello, Mario ^a   Tacconelli, Evelina ^a   Amore, Concetta ^c   Cauda, Roberto ^a   Lacoviello, Licia ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VIRUS RNA;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID METABOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HUMANS; LINEAR MODELS; MALE;

EID: 0037471267     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200303280-00020     Document Type: Article

References (18)

1. Ridker PM, Hennekens CH, Roitman-Jhonson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently healthy men. Lancet 1998, 351:88-92.
2. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyriakopoulos A. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM and E-selectin in human atherosclerosis. J Pathol 1993, 171:223-229.
3. Blankenberg S, Rupprecht H, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001, 104:1336-1342.
4. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001, 103:491-495.
5. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993, 341:1165-1168.
6. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987, 2:3-9.
7. Teitel JM, Shore A, Read SE, Schiarone A. Immune function of vascular endothelial cells is impaired by HIV. J Infect Dis 1989, 160:551-552.
8. Lafeuillade A, Alessi MC, Poizot-Martin I, Boyer-Neumann C, Zandotti C, Quilichini R, et al. Endothelial cell dysfunction in HIV infection. J Acquired Immune Defic Syndr 1992, 5:127-131.
9. Puppo F, Brenci S, Scudeletti M, Lanza L, Bosco O, Indiveri F. Elevated serum levels of circulating intercellular adhesion molecule-1 in HIV infection. AIDS 1993, 7:593-594.
10. Seigneur M, Constans J, Blann A, Renard M, Pellegrin JL, Amiral J, et al. Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb Haemost 1997, 77:646-649.
11. Aukrust P, Bjornsen S, Lunden B, Otterdal K, Ng EC, Ameln W, et al. Persistently elevated levels of von Willebrand factor antigen in HIV infection. Thromb Haemost 2000, 84:183-187.
12. Sipsas N, Sfikakis PP, Sfikakis P, Choremi H, Kordossis T. Serum concentrations of soluble intercellular adhesion molecule-1 and progress towards disease in patients infected with HIV. J Infect 1994, 29:271-282.
13. Galea P, Vermont-Desroches C, Le Contel C, Wijdenes J, Chermann JC. Circulating cell adhesion molecules in HIV-1 infected patients as indicator markers for AIDS progression. Res Immunol 1997, 148:109-117.
14. Mastroianni CM, Lichtner M, Mengoni F, D'Agostino C, d'Ettorre G, Forcina G, et al. Changes in circulating levels of soluble cell adhesion molecules following highly active antiretroviral treatment of HIV-1-infected patients. Clin Immunol 2000, 95:212-217.
15. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otuos JD, Sosman JM. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001, 104:57-62.
16. Hadigan C, Meigs JB, Rabe J, D'Agostino RB, Wilson PW, Lipinska I, et al. Increased PAl-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001, 86:939-943.
17. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidemia, an insuline resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
18. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave J-P, et al. Premature atherosclerosis in HIV-infected individuals - focus on protease inhibitor therapy. AIDS 2001, 15:329-334.